Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.66 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.33 |
| ▸ | TACR3 | P29371 | 3/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MITF | O75030 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3045958 | 1.00 | CTSB (0.66) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL3050936 | 0.94 | CTSB (0.63) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL3050935 | 0.94 | CTSB (0.63) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL3052431 | 0.91 | CTSB (0.82) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL13248865 | 0.91 | CTSB (0.82) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL13385376 | 0.88 | CTSB (0.55) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL3048931 | 0.88 | CTSB (0.55) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL3283647 | 0.88 | CTSB (0.55) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL3046722 | 0.88 | CTSB (0.55) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL13519885 | 0.88 | CTSB (0.55) | CTSBCTSSADRB3ADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10172846-B2 | HCV NS-3 serine protease inhibitors | MEDIVIR AB (SE) | 2019-01-08 | — | — | US | disclosed |
| US-10172846-B2 | HCV NS-3 serine protease inhibitors | MEDIVIR AB (SE) | 2019-01-08 | — | — | US | disclosed |
| US-20170196849-A1 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2017-07-13 | — | — | US | disclosed |
| US-20170196849-A1 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2017-07-13 | — | — | US | disclosed |
| US-20170196849-A1 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2017-07-13 | — | — | US | disclosed |
| US-20100166706-A1 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2010-07-01 | — | — | US | disclosed |
| US-20100166706-A1 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2010-07-01 | — | — | US | disclosed |
| US-20100166706-A1 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2010-07-01 | — | — | US | disclosed |
| US-7671032-B2 | HCV NS-3 serine protease inhibitors | MEDIVIR AB (SE) | 2010-03-02 | — | — | US | disclosed |
| US-7671032-B2 | HCV NS-3 serine protease inhibitors | MEDIVIR AB (SE) | 2010-03-02 | — | — | US | disclosed |
| US-7671032-B2 | HCV NS-3 serine protease inhibitors | MEDIVIR AB (SE) | 2010-03-02 | — | — | US | disclosed |
| EP-1713823-B1 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2009-11-11 | — | — | EP | disclosed |
| US-20070203072-A1 | Hcv Ns-3 Serine Protease Inhibitors | MEDIVIR AB (SE) | 2007-08-30 | — | — | US | disclosed |
| US-20070203072-A1 | Hcv Ns-3 Serine Protease Inhibitors | MEDIVIR AB (SE) | 2007-08-30 | — | — | US | disclosed |
| US-20070203072-A1 | Hcv Ns-3 Serine Protease Inhibitors | MEDIVIR AB (SE) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100166706-A1 | HCV NS-3 SERINE PROTEASE INHIBITORS | HPN, CPN1, PRSS1 | CTSB 168/4885CTSS 89/4885ADRB3 4099/4885 |
| US-20170196849-A1 | HCV NS-3 SERINE PROTEASE INHIBITORS | HPN, CPN1, PRSS1 | CTSB 168/4885CTSS 89/4885ADRB3 4099/4885 |
| US-20070203072-A1 | Hcv Ns-3 Serine Protease Inhibitors | HPN, CPN1, PRSS1 | CTSB 126/4885CTSS 69/4885ADRB3 4075/4885 |
| US-10172846-B2 | HCV NS-3 serine protease inhibitors | HPN, CPN1, PRSS1 | CTSB 168/4885CTSS 89/4885ADRB3 4099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.